Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

755

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

July 31, 2020

Study Completion Date

June 30, 2021

Conditions
COVID-19SARS-CoV-2 Infection
Interventions
BIOLOGICAL

BBV152A - Phase I

0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14

BIOLOGICAL

BBV152B - Phase I

0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14

BIOLOGICAL

BBV152C - Phase I

0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14

BIOLOGICAL

Placebo - Phase I

0.5 ml of the Placebo will be administered intramuscularly twice at Day 0 and Day 14

BIOLOGICAL

BBV152A - Phase II

0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 28

BIOLOGICAL

BBV152B - Phase II

0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 28

Trial Locations (12)

110029

All India Institute of Medical Sciences, Delhi

124001

Pt BD SHARMA,PGIMS/UHS, Rohtak

208002

Prakhar Hospital, Kanpur

273013

Rana Hospital and Trauma Center, Gorakhpur

403513

Redkar Hospital and Research Centre, Goa

440009

Gillukar Multispeciality Hospital, Nagpur

500082

Nizam's Institute of Medical Sciences, Hyderabad

560037

King George Hospital, Visakhapatnam

590019

Jeevan Rekha Hospital, Belagavi

603211

SRM Hospital & Research center, Chennai

751003

Institute of Medical Sciences and SUM Hospital, Bhubaneswar

801507

All India Institute of Medical Sciences, Patna

All Listed Sponsors
collaborator

Indian Council of Medical Research

OTHER_GOV

lead

Bharat Biotech International Limited

INDUSTRY

NCT04471519 - Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers | Biotech Hunter | Biotech Hunter